Regeneron Pharmaceuticals | REGN - Equity Capital And Reserves


Regeneron Pharmaceuticals reported $31.42B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Agenus USD -221.22M 49.89M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Astellas Pharma JPY 1.83T 65.92B Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Kyowa Hakko Kirin JPY 892.74B 591M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 73.14B 1.43B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026